[New antitubercular drugs].
Krasucka-Kluźniak
A
A
Kliniki Gruźlicy i Chorób Płuc Instytutu Gruźlicy i Chorób Płuc.
D000818:Animals; D000995:Antitubercular Agents / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D002939:Ciprofloxacin / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D002991:Clofazimine / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D006801:Humans; D066298:In Vitro Techniques; D051379:Mice; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D015242:Ofloxacin / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D017828:Rifabutin; D012294:Rifamycins / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D014376:Tuberculosis / Q000188:drug therapy* / Q000382:microbiology
D000995:Antitubercular Agents; D012294:Rifamycins; D017828:Rifabutin; D002939:Ciprofloxacin; D015242:Ofloxacin; D002991:Clofazimine
Nowe leki przeciwpratkowe.